Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi-Aventis’ Taxotere Gains New Indication For Head And Neck Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

Approval is based on data showing progression-free survival of 11.4 months.

You may also be interested in...

Taxotere Promotional Efforts Will Focus On Metastatic Breast Cancer

Taxotere promotional efforts regarding metastatic breast cancer use will be a "major field of activity during the months to come in the U.S.," Sanofi-Aventis Exec VP-Pharmaceutical Operations Hanspeter Spek said

Erbitux Pricing Could Be Modified With Longer Treatment Cycles

Cetuximab was approved March 1 for treatment of advanced head and neck cancer.

Novartis Institute For Tropical Diseases Could Have TB Drug In Clinic By Late 2007

Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts